MTOR and renal cell carcinoma: Chronic exposure of sorafenib-resistant RCC cells to sorafenib inhibits ERK activation of [10], sequentially reduces mTOR independent of the PI3K/Akt pathway [11], and activates Akt via a feedback loop.